RxDoctor Payments Data

Stan Wasilewski, MD

Clinical Cardiac Electrophysiology · Edison, NJNPI 1841240132

Payments from drug & device makers

$2,368in general payments, 2019–2025

Across 101 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$423
  • Cvrx, Inc.$330
  • Novo Nordisk$255
  • Impulse Dynamics (USA) Inc.$152
  • Pfizer$139
  • Abbott$121
  • plus $948 from 21 others

What the payments were for

  • Food & beverage$2,34699%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,368 in reported general payments places this provider in the 5th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$431,938
Medicare patients
1,972
Services billed
6,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban316$375,160
VyndamaxTafamidis13$276,094
MultaqDronedarone Hcl60$112,941
XareltoRivaroxaban87$99,219
EntrestoSacubitril/Valsartan49$71,199
JardianceEmpagliflozin53$69,260
BrilintaTicagrelor36$30,405
Metoprolol Succinate510$8,089
Diltiazem 24hr Er (Cd)Diltiazem Hcl132$4,952
Valsartan124$3,730
Nebivolol Hcl56$3,716
Dexlansoprazole DrDexlansoprazole14$3,656
Atorvastatin Calcium292$3,003
Amiodarone Hcl28$2,534
Flecainide Acetate64$2,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$139$651,255329 claims
Sanofi-aventis U.S. LLCMultaq$55$112,94160 claims
Johnson & JohnsonXarelto$44$99,21987 claims
NovartisEntresto$64$71,19949 claims
Boehringer IngelheimJardiance$60$69,26053 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →